IMMA Health Raises $5M Seed Round to Revolutionize At-Home Fertility Monitoring

IMMA Health, a pioneering women-led venture from Israel, is excited to announce that it has successfully raised $5,000,000 in funding to further advance its groundbreaking technology in women’s health. Focused on revolutionizing the rapidly expanding fertility market, IMMA Health is developing an at-home ovarian stimulation monitoring system that empowers women by offering an intimate and convenient solution for tracking their reproductive health. At the core of IMMA’s innovation is its remote, automated intra-vaginal ultrasound device paired with sophisticated AI-powered image analysis, which enables women to monitor their follicle stimulation progress safely and accurately from the comfort of their own homes. This breakthrough not only saves valuable time for both physicians and patients but also reduces the stress and inconvenience associated with frequent office visits, elevating the overall standard of care. The infusion of capital will be dedicated to further research and development, scaling the system’s capabilities, and expanding its outreach beyond the initial IVF market. Recognizing that women’s health extends far beyond fertility, IMMA Health envisions its technology becoming a comprehensive platform that supports hormone-free contraception, fertility enhancement, and the early detection of various pathologies and cancers throughout a woman’s life. By empowering women to take control of their healthcare journey, the company underscores its commitment to innovation and accessible, high-quality medical care. This funding milestone marks a significant step forward, promising enhanced efficiency in treatment monitoring while fostering broader access to state-of-the-art diagnostic technologies designed with women’s unique needs in mind.